Thursday 16 October, 2025
Objectives: Crenezumab is an antibody to treat Alzheimer’s Disease (AD). Two Phase 2 studies in mild-to-moderate AD patients evaluated a high…
Read morePoster: Drug/Disease Modelling - CNS
Pharmacometric characterization of the reserpine-induced fibromyalgia model in rats to support a model-informed dosing regimen strategy for alternative disease status conditions
Thursday 16 October, 2025
Introduction: Reserpine administration has been used to generate fibromyalgia (FM) disease in rodents by reproducing both the main symptom (generalized musculoskeletal…
Read morePopulation Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia
Thursday 16 October, 2025
Objectives: To describe lemborexant PK and quantify the effects of intrinsic and extrinsic factors in healthy adults, elderly, and in…
Read moreComponent score models of HAMD were more predictive than total score models
Thursday 16 October, 2025
Objectives: SAGE-217 is a potent investigational GABAA receptor modulator at both synaptic and extrasynaptic receptor subtypes, and is currently being…
Read moreSimulations of tau-targeted therapies using quantitative systems pharmacology model of tau pathology
Thursday 16 October, 2025
Objectives: Accumulation of pathological forms of tau protein is one of the key hallmarks of neurodegenerative diseases. Unlike amyloid pathology, tau…
Read morePharmacokinetic/Pharmacodynamic effects of PF-06648671, a novel gamma secretase modulator following single and multiple dose administration in healthy volunteers
Thursday 16 October, 2025
Objectives: Gamma secretase modulators (GSMs) shift the cleavage of amyloid-β (Aβ) peptides in favor of shorter forms (such as Aβ37…
Read moreQuantitative systems pharmacology model of axonal degeneration markers in Alzheimer’s disease
Thursday 16 October, 2025
Objectives: Progress in the treatment of neurodegenerative disease is limited by long duration of clinical trials required to establish clinical…
Read moreAmyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects
Thursday 16 October, 2025
Objectives: Clinical trials for Alzheimer’s disease (AD) are focused at present time mostly at clearing different forms of accumulated amyloid…
Read moreA systems pharmacology approach unravels the dynamics of the APP pathway and unfolds Aß oligomer modulation
Thursday 16 October, 2025
Objectives: In Alzheimer’s Disease, amyloid-β (Aβ) levels are increased early forming toxic soluble Aβ oligomers (AβO) and plaques. Drug effects…
Read morePopulation Pharmacokinetic Analysis of Tanezumab, a Novel Monoclonal Antibody to Nerve Growth Factor, Following Intravenous or Subcutaneous Administration to Patients with Osteoarthritis or Chronic Low Back Pain in Phase 2b and Phase 3 Studies
Thursday 16 October, 2025
Introduction: Tanezumab is a monoclonal antibody that binds to and inhibits the actions of nerve growth factor (NGF). The NGF…
Read more